Therapeutic Asset Ratings
212 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cadvec
Gastric Cancer
Baylor College of Medicine
P1
C
(37)
cct303-406
Gastric Cancer
Shanghai PerHum Therapeutics Co., Ltd.
P1
C
(37)
cirtociclib
Gastric Cancer
Blueprint Medicines Corporation
P1
C
(37)
Claudin 18.2 Car-T
Gastric Cancer
Suzhou Immunofoco Biotechnology Co., Ltd
P1
C
(37)
cpo102
Gastric Cancer
Conjupro Biotherapeutics, Inc.
P1
C
(37)
CRX100
Gastric Cancer
BioEclipse Therapeutics
P1
C
(37)
Dat-2645
Gastric Cancer
Danatlas Pharmaceuticals Co., Ltd
P1
C
(37)
dr-0202
Gastric Cancer
Dren Bio
P1
C
(37)
Emunkitug
Gastric Cancer
HiFiBiO Therapeutics
P1
C
(37)
exs74539
Gastric Cancer
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
C
(37)
Fpi-2053
Gastric Cancer
AstraZeneca
P1
C
(37)
hfb200603
Gastric Cancer
HiFiBiO Therapeutics
P1
C
(37)
H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV3-23*01 (81.6%) -(IGHD) -IGHJ3*02 (91.7%) M123>T (114), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*03v (100%) G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-218')-disulfide with L-kappa light chain humanized (1'-218') [VKAPPA (Homo sapiens IGKV1-33*01 (87.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPAA45.1 (157'), V101 (195')) (112'-218')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
Gastric Cancer
Genentech, Inc.
P1
C
(37)
Idov-Immune
Gastric Cancer
ViroMissile, Inc.
P1
C
(37)
iks014
Gastric Cancer
Iksuda Therapeutics Ltd.
P1
C
(37)
Immunoglobulin G1 [de-236-glycine,267-glutamic acid,de-C-terminal lysine], anti-(human tumor necrosis factor receptor TNFRSF9) (human-Mus musculus monoclonal LVGN6051 ?1-chain), disulfide with human-Mus musculus monoclonal LVGN6051 ?-chain, dimer
Gastric Cancer
M.D. Anderson Cancer Center
P1
C
(37)
Immunoglobulin G1 [de-236-glycine,de-C-terminal lysine], anti-(human CD40 antigen) (human monoclonal LVGN7409 ?1-chain), disulfide with human monoclonal LVGN7409 ?-chain, dimer
Gastric Cancer
M.D. Anderson Cancer Center
P1
C
(37)
immunoglobulin G1-kappa, anti-[Homo sapiens TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-48*01 (90.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>A (236), L1.2>A (237) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (89.5%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa
Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
ivx037
Gastric Cancer
ImmVirx Pty Ltd
P1
C
(37)
jr8603
Gastric Cancer
JiaRay Group
P1
C
(37)
Kk-Lc-1 Tcr-T Cells
Gastric Cancer
Christian Hinrichs
P1
C
(37)
lb1908
Gastric Cancer
Legend Biotech USA Inc
P1
C
(37)
LEUPROLIDE
Gastric Cancer
Blueprint Medicines Corporation
P1
C
(37)
MGC026
Gastric Cancer
MacroGenics
P1
C
(37)
MNPR-101-DFO-89Zr
Gastric Cancer
Monopar Therapeutics
P1
C
(37)
Showing 151 to 175 of 212 assets
Previous
Page 7 of 9
Next
